Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Zhiyue Rao, Yu Yao et al.|Nature Medicine|2025Cited by 30
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort studyShujing Shen, Ningning Yan, Xingya Li et al.|Frontiers in Oncology|2024Cited by 7
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancerShun Lü, Yibin Wang, Yongfeng Yu et al.|Translational Lung Cancer Research|2025Cited by 2